BioMarin to Acquire Alesta Therapeutics for Hypophosphatasia Program
BioMarin (BMRN) announces an acquisition of Alesta Therapeutics to gain ALE1, described as a potential first oral therapy for hypophosphatasia, adding a clinical program to its pipeline.